55.21
-3.46 (-5.90%)
| Previous Close | 58.67 |
| Open | 58.22 |
| Volume | 255,587 |
| Avg. Volume (3M) | 272,495 |
| Market Cap | 368,945,472 |
| Price / Book | 2.85 |
| 52 Weeks Range | |
| Earnings Date | 24 Mar 2026 |
| Diluted EPS (TTM) | -3.98 |
| Current Ratio (MRQ) | 36.92 |
| Operating Cash Flow (TTM) | -10.41 M |
| Levered Free Cash Flow (TTM) | -9.22 M |
| Return on Assets (TTM) | -34.49% |
| Return on Equity (TTM) | -54.27% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Monopar Therapeutics Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -5.0 |
| Average | 0.13 |
|
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 34.38% |
| % Held by Institutions | 47.24% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 115.00 (Morgan Stanley, 108.30%) | Buy |
| Median | 104.00 (88.37%) | |
| Low | 100.00 (Chardan Capital, 81.13%) | Buy |
| Average | 106.33 (92.59%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 62.05 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| BTIG | 23 Feb 2026 | 104.00 (88.37%) | Buy | 55.80 |
| 02 Feb 2026 | 104.00 (88.37%) | Buy | 65.48 | |
| Chardan Capital | 29 Jan 2026 | 100.00 (81.13%) | Buy | 67.34 |
| Morgan Stanley | 09 Jan 2026 | 115.00 (108.30%) | Buy | 63.00 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |